Fascination with stem cell sensation leads to Fulbright scholarship – Monash University

You are here:

12 May 2021

PhD student Meg McFetridge has received a coveted Fulbright Future Scholarship

Meg McFetridge was first inspired by mechanobiology in her honours year, watching stem cells on hydrogel surfaces. One end of the hydrogel was soft, the other end stiff, with a stiffness gradient in between. When the stem cells felt the soft end they became fat; on the stiff end they turned to bone. I couldnt get it out of my head.

Four years later that fascination, her aptitude and a project Meg has devised as a PhD student have earned her a coveted Fulbright Future Scholarship for postdoctoral research at Cornell University, Ithaca, New York for eight months.

I was completely speechless, she said of the news. The woman on the end of the phone who told me Id got the scholarship was so excited; I was barely able to speak.

The Fulbright is highly prestigious, its a great thing for Monash too. It demonstrates the quality of the doctoral program that it can produce highly competitive postdoctoral scholars.

The Fulbright Program is the flagship foreign exchange scholarship program of the US. Its Future Scholarship will provide Meg with, among other benefits, a monthly stipend, full visiting researcher scholar fees, a round-trip airfare to New York, enrichment opportunities in Australia and the US with other international Fulbright scholars, and access to a professional network of distinguished Australian and American Fulbright alumni.

Meg, who will submit her PhD in August, works in her primary supervisor Professor Sharon Ricardos lab and is co-supervised by Professor Mibel Aguilar and Dr Mark Del Borgo.

She will conduct research in the US into a project she has devised in mechano-microscopy.

Cells and tissues push and pull on their surrounds to feel out where they are and what they need to do, she said. Mechano-microscopy is an umbrella term for a group of microscopy techniques that allow us to look at the complex relationship between cells and their physical environment. The Adie lab at Cornell University has developed a microscope thats one of a kind it combines multiple microscopy modes to get a complete picture of this interaction.

This microscope will allow us to tackle fundamental research questions in mechanobiology that have previously been near impossible to answer.

Meg moved to Monash, having completed honours at the University of Western Australia, after reading about a project for her PhD. This project offered me new challenges because its more translational than my previous work. The other thing about Monash is we have excellent facilities and a thriving research community which attracted me to make the move.

Her PhD project aimed to develop hydrogels to deliver stem cell therapy. In the long term were working towards safe and effective stem cell therapy for a broad range of diseases; in the short term were doing basic science to understand how we can create artificial environments that guide stem cells in the right direction.

During my PhD the fascination with mechanobiology was nagging me to ask what the cells were feeling in my hydrogels, but I didnt have the scope or the facilities to do so; thats why I need to go to Cornell, she said.

Meg, who will leave for the US early next year, hopes to act as a bridge between the fantastic research community here and researchers overseas who have the specialist equipment and are making advances in the field.

She has previously won poster awards at local and international conferences and was selected by Monash to be one of 35 students globally to take part in the two-week intensive SPARK Global Biomedical Innovation and Entrepreneurship Training Course in August 2019.

There were 81 Australian Fulbright awardees this year: 41 students and 40 scholars (including Meg).

About the Monash Biomedicine Discovery Institute at Monash UniversityCommitted to making the discoveries that will relieve the future burden of disease, the newly establishedMonash Biomedicine Discovery Institute at Monash University brings together more than 120 internationally-renowned research teams. Spanning six discovery programs across Cancer, Cardiovascular Disease, Development and Stem Cells, Infection and Immunity, Metabolism, Diabetes and Obesity, and Neuroscience, Monash BDI is one of the largest biomedical research institutes in Australia.Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery

Media EnquiriesMonash Media - Wendy SmithT: +61 425 725 836E:wendy.smith1@monash.edu

Read the rest here:

Fascination with stem cell sensation leads to Fulbright scholarship - Monash University

Read more
The Competitive Zeal To Decide The Dimensions Of Growth Of The Induced Pluripotent Stem Cells Market The Courier – The Courier

Virtual reality is amongst the revolutionary trends driving the healthcare industry. The Induced Pluripotent Stem Cells Market report by Persistence Market Research harps on the way virtual reality has taken the healthcare industry by storm. VR-based healthcare solutions have been captured, with insights regarding the same. Micros have been worked upon.

The healthcare industry has been focusing on excessive research and development in the last couple of decades to ensure that the need to address issues related to the availability of drugs and treatments for certain chronic diseases is effectively met. Healthcare researchers and scientists at the Li Ka Shing Faculty of Medicine of the Hong Kong University have successfully demonstrated the utilization of human induced pluripotent stem cells or hiPSCs from the skin cells of the patient for testing therapeutic drugs.

The success of this research suggests that scientists have crossed one more hurdle towards using stem cells in precision medicine for the treatment of patients suffering from sporadic hereditary diseases. iPSCs are the new generation approach towards the prevention and treatment of diseases that takes into account patients on an individual basis considering their genetic makeup, lifestyle, and environment. Along with the capacity to transform into different body cell types and same genetic composition of the donors, hiPSCs have surfaced as a promising cell source to screen and test drugs.

Get Sample Copy of Report @https://www.persistencemarketresearch.com/samples/17968

Company Profile

Get To Know Methodology of Report @https://www.persistencemarketresearch.com/methodology/17968

In the present research, hiPSC was synthesized from patients suffering from a rare form of hereditary cardiomyopathy owing to the mutations in Lamin A/C related cardiomyopathy in their distinct families. The affected individuals suffer from sudden death, stroke, and heart failure at a very young age. As on date, there is no exact treatment available for this condition.

This team in Hong Kong tested a drug named PTC124 to suppress specific genetic mutations in other genetic diseases into the iPSC transformed heart muscle cells. While this technology is being considered as a breakthrough in clinical stem cell research, the team at Hong Kong University is collaborating with drug companies regarding its clinical application.

The unique properties of iPS cells provides extensive potential to several biopharmaceutical applications. iPSCs are also used in toxicology testing, high throughput, disease modeling, and target identification. This type of stem cell has the potential to transform drug discovery by offering physiologically relevant cells for tool discovery, compound identification, and target validation.

A new report by Persistence Market Research (PMR) states that the globalinduced pluripotent stem or iPS cell marketis expected to witness a strongCAGR of 7.0%from 2018 to 2026. In 2017, the market was worthUS$ 1,254.0 Mnand is expected to reachUS$ 2,299.5 Mnby the end of the forecast period in 2026.

Access Full Report @https://www.persistencemarketresearch.com/checkout/17968

Customization to be the Key Focus of Market Players

Due to the evolving needs of the research community, the demand for specialized cell lines have increased to a certain point where most vendors offering these products cannot depend solely on sales from catalog products. The quality of the products and lead time can determine the choices while requesting custom solutions at the same time. Companies usually focus on establishing a strong distribution network for enabling products to reach customers from the manufacturing units in a short time period.

Entry of Multiple Small Players to be Witnessed in the Coming Years

Several leading players have their presence in the global market; however, many specialized products and services are provided by small and regional vendors. By targeting their marketing strategies towards research institutes and small biotechnology companies, these new players have swiftly established their presence in the market.

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers experience by acting as the missing link between customer relationships and business outcomes. The best possible returns are assured therein.

Contact Us:

Persistence Market ResearchAddress 305 Broadway, 7th Floor, New York City, NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Salessales@persistencemarketresearch.comWebsite https://www.persistencemarketresearch.com

Follow this link:

The Competitive Zeal To Decide The Dimensions Of Growth Of The Induced Pluripotent Stem Cells Market The Courier - The Courier

Read more
Gene therapy offers potential cure to children born without an immune system – UCLA Newsroom

An experimental form of gene therapy developed by a team of researchers from UCLA and Great Ormond Street Hospital in London has successfully treated 48 of 50 children born with a rare and deadly inherited disorder that leaves them without an immune system.

Severe combined immunodeficiency due to adenosine deaminase deficiency, or ADA-SCID, is caused by mutations in the ADA gene that creates the enzyme adenosine deaminase, which is essential to a functioning immune system. For children with the condition, even day-to-day activities like going to school or playing with friends can lead to dangerous, life-threatening infections. If untreated, ADA-SCID can be fatal within the first two years of life.

The investigational gene therapy method involves first collecting some of the childs blood-forming stem cells, which have the potential to create all types of blood and immune cells. Next, using an approach developed by the research team, a new copy of the ADA gene is delivered into the stem cells by a modified lentivirus, or viral vector. The corrected cells are then returned to the childs body, where they are intended to produce a continual supply of healthy immune cells capable of fighting infection.

In a studypublished today in the New England Journal of Medicine, co-lead authors Dr. Donald Kohn of UCLA and Dr. Claire Booth of Great Ormond Street Hospital, or GOSH, report two- and three-year outcomes for children treated with the investigational lentiviral gene therapy in clinical trials at GOSH, UCLA Mattel Childrens Hospital and the National Institutes of Health between 2012 and 2017.

Between all three clinical trials, 50 patients were treated, and the overall results were very encouraging, said Kohn, a distinguished professor of microbiology, immunology and molecular genetics and a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. All the patients are alive and well, and in more than 95% of them, the therapy appears to have corrected their underlying immune system problems.

No complications or treatment-limiting events were reported among the patients. Most adverse events were mild or moderate, and were considered to be related to routine procedures performed in preparation for the experimental gene therapy treatment or effects of the immune system rebuilding.

Treatment was successful in all but two of the 50 cases, and both of those children were able to return to current standard-of care-therapies and treatments, with one eventually receiving a bone marrow transplant, said Kohn, who has been working to develop gene therapies for ADA-SCID and other blood diseases for 35 years.

The investigational gene therapy a one-time procedure that the researchers say may provide lifelong results is a welcome potential new treatment option for children with ADA-SCID, who otherwise must undergo once- or twice-weekly injections of the ADA enzyme until a matched bone marrow donor, usually a close family member, can be found. If a donor is not available, patients require lifelong injections, along with antibiotics, antifungal medications and monthly infusions of immunoglobulin, which contains infection-fighting antibodies. These treatments are expensive and therefore out of reach for patients in many countries.

If approved in the future, this treatment could be standard for ADA-SCID, and potentially many other genetic conditions, removing the need to find a matched donor for a bone marrow transplant and the toxic side effects often associated with that treatment, said Booth, a GOSH consultant inpediatric immunology and genetherapy.

The benefits of lentiviral gene therapy

Prior to teaming up, both Booth and Kohn worked separately for years onsuccessful gene therapiesfor ADA-SCID that used viral vectors made from retroviruses. Retroviral vectors, however, can only enter cells nuclei to deliver genes while the cells are dividing, limiting the number of cells receiving the genetic payload and, thereby, the potential efficacy of the treatment.

Additionally, while neither Kohn nor Booth observed serious complications in their ADA-SCID trials, other earlier studies testing retroviral vector-based gene therapies did report some serious side effects, including leukemia, in some patients.

In 2008, Booth and Kohn began collaborating with professors Bobby Gaspar and Adrian Thrasher of University College London to develop an improved viral vector using a different kind of virus, called a lentivirus. Viruses of this kind can enter non-dividing cells nuclei and, when used as vectors, have the potential to make gene therapies safer and more effective. ADA-SCID patients began receiving the new gene therapy at GOSH in 2012; the following year, the experimental treatment was offered at UCLA and the NIH.

More than 200 patients with various genetic conditions across the worldhave now been treatedwith experimental lentiviral gene therapies, and applying gene therapy to ADA-SCIDis another significantscientific advance, said Thrasher, a senior author of the study who is also a professor of pediatric immunology at GOSH.

Ten of the children in the UCLA study were treated using a frozen preparation of corrected stem cells. These children experienced similar outcomes to the children treated with cells that were not frozen. The freezing approach may allow children with ADA-SCID to have their stem cells collected locally, then have them transported and processed at a manufacturing facility elsewhere and shipped back to a specialized hospital near them, removing the need for patients and their families to travel long distances to specialist centers.

One patients story: A life-changing treatment

Courtesy of Chelsea Oakley

One of the patients who received a frozen preparation of cells at UCLA, Cora Oakley of Morristown, New Jersey, was diagnosed with ADA-SCID through newborn genetic screening at just 7 days old, in April 2017.I remember asking the doctor if my daughter was going to die, Coras mother, Chelsea Oakley, said of receiving the diagnosis. And his response was, I hope not. It was the darkest day of my life.

Cora was the last child to enroll in the clinical trial and received her own corrected cells in September 2017.Following the gene therapy, Cora and her family spent a month in the bone marrow transplant unit of a hospital closer to their home for Coras follow-up treatment. The experiences of the other young patients in this unit opened Oakleys eyes to what her daughter would have gone through if the experimental gene therapy hadnt been an option.

I saw young bone marrow transplant patients who developed graft-versus-host disease and others who had to take all these anti-rejection medications and still had issues. I just thought no one should have to suffer like this, she said. And then heres my daughter who had this life-changing treatment that felt like a miracle. It still shocks me all the time how unbelievably fortunate we are.

Now a healthy and exuberant 4-year-old, Cora is described by her mom as a rough and tumble, outdoors kind of kid who loves all animals and is incredibly social. Ill never forget what it felt like when we didnt know if shed ever be able to do any of these things, Oakley said.

The investigational lentiviral gene therapy is licensed to Orchard Therapeutics and has not been approved for clinical use by any regulatory authority.

The research was funded by the National Institute of Allergy and Infectious Diseases, the National Heart, Lung and Blood Institute, and the National Human Genome Research Institute (all part of the U.S. National Institutes of Health); the California Institute for Regenerative Medicine; the U.K. National Institute for Health Researchs Biomedical Research Centre at Great Ormond Street Hospital for Children National Health Service Foundation Trust, University College London and Orchard Therapeutics.

See the original post here:

Gene therapy offers potential cure to children born without an immune system - UCLA Newsroom

Read more
Advanced Therapy Medicinal Products Market Size Worth $21.2 Billion By 2028: Grand View Research, Inc. – PRNewswire

SAN FRANCISCO, May 12, 2021 /PRNewswire/ -- The global advanced therapy medicinal products marketsize is expected to reach USD 21.2billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 13.2% from 2021 to 2028.The ATMPs (Advanced Therapy Medicinal Products) exhibit the potential to cure diseases by addressing their root cause rather than symptomatic treatment. Thus, ATMPs help deliver transformative advantages which are not offered by conventional treatments. These factors are expected to drive the market over the forecast period.

Key suggestions from the report:

Read 225 page research report with ToC on "Advanced Therapy Medicinal Products Market Size, Share & Trends Analysis Report By Therapy Type (CAR-T, Gene, Cell, Stem Cell Therapy), By Region (North America, Europe, APAC, ROW), And Segment Forecasts, 2021 - 2028" at: https://www.grandviewresearch.com/industry-analysis/advanced-therapy-medicinal-products-market

The breakthrough approvals of Tecartus and Abecma post-approval of Zolgensma, Kymriah, and Yescarta have bolstered the exceptional advancements in this space. These approvals have spurred the investment flow in this arena thereby driving revenue growth. Key companies are adopting various operation models to accelerate the product manufacturing process.

Furthermore, the market witnessed several acquisitions by players that intended to enter or expand their existing business in this field. Acquisitions of Kite Pharma by Gilead Life Science, AveXis by Novartis, and Juno Therapeutics by Celgene are some major & recent examples. These acquisitions depict the increasing interest of well-established pharma companies in this market. Increasing competition for gene therapy buyouts can lead to hefty premiums.

On the other hand, with the growing consumer demands, the ATMP manufacturers are outsourcing their product manufacturing thereby creating lucrative opportunities for the contract manufacturing organizations. Thus, several CDMOs have expanded their facilities. For instance, in January 2021, FUJIFILM Diosynth Biotechnologies invested USD 40 million for the establishment of a new process development and manufacturing facility for advanced therapies and viral vectors.

Grand View Research has segmented the global advanced therapy medicinal products market on the basis of therapy type and region:

List of Key Players in Advanced Therapy Medicinal Products (ATMPs) Market

Find more research reports on Pharmaceuticals Industry, by Grand View Research:

Gain access to Grand View Compass,our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.


Sherry JamesCorporate Sales Specialist, USAGrand View Research, Inc.Phone: +1-415-349-0058Toll Free: 1-888-202-9519Email: [emailprotected]Web: https://www.grandviewresearch.comFollow Us: LinkedIn| Twitter

SOURCE Grand View Research, Inc.

Read more from the original source:

Advanced Therapy Medicinal Products Market Size Worth $21.2 Billion By 2028: Grand View Research, Inc. - PRNewswire

Read more
With $52 Million Series A, Appia Bio Anticipates a Bright Future in Cell Therapy – BioSpace

Appia co-founder and chief executive officer, JJ Kang/Photo Courtesy of Appia Bio

Backed by $52 million in Series A financing led by 8VC and named after a feat of engineering in ancient Rome, Appia Bio jumped into the cell therapy fray this morning with a promising scalable technology platform.

The company is named after the Aqua Appia, which is the first Roman aqueduct. It was kind of a feat of engineering and it brought water to a lot more people, and that thematically connects well. We want to engineer these cells and provide a broader reach for cell therapy through allogeneic off-the-shelf, said Appia co-founder and chief executive officer, JJ Kang, Ph.D.

Appia is developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients. Its ACUA platform utilizes the biology of lymphocyte development with CAR and TCR gene engineering to produce CAR-engineered invariant natural killer T (CAR-iNKT) cells from HSCs.

The Los Angeles-based biotech is spun out of the pioneering work ofLili Yang, Ph.D., an associate professor at the University of California, Los Angeles (UCLA).

In addition to the $52 million votes of confidence provided by 8VC, Two Sigma Ventures, and seed investors, Sherpa Healthcare Partners and Freeflow Ventures, Appias newly announced scientific board is packed to the brim with wisdom.

Appia is co-founded by Nobel laureate winner and former president of theCalifornia Institute of Technology, Dr. David Baltimore. Edmund Kim, Ph.D., former VP of corporate development atKite Pharma(Gilead Sciences), comes on board as chief operating officer, while Jeff Wiezorek, MD, former head of cell therapy development at Kite and a previous student of Baltimores, joins as chief medical officer.

One of those guys, Jeff, has been a post-doc with me, so hes well-trained, quipped Baltimore.

In an exploding and crowded field, how does Appia differentiate itself?

I think in being an off-the-shelf allogeneic cell, charged and ready to go, said Baltimore. The secret here is Lili Yang, who figured out how to grow very large numbers of iNKT cells from a single harvest of hematopoietic stem cells. So we can make large numbers of cells to treat many multiples of patients from a single donor source. And we can prepare that ahead of time. So that means that no matter what their own HLA [human leukocyte antigen] is, these cells can be used therapeutically.

AQUA is also able to leverage these iNKT cells in a scaleable manner.

The big step forward with this technology is that starting from these hematopoietic stem cells, we can drive to the these invariant NKT cells that are actually naturally quite rare. Through this platform, we can produce a lot of these cells and do so in a scaleable, fullyex vivomanner that gives us a path forward for industry use for commercialization, said Kang.

Appia is now ready to power its extensive research forward into the clinic.

We have space now and we have money, we have people, said Baltimore. Were in the process of the technology transfer. The second step is to show that it will work in animal systems. Lili has done that, but we want to be able to show that we can do that. Then is the big step: Preparing ourselves for initial clinical trials. That will be a little ways down the road, but with the investments that we have now, we should be in a position to carry that step through.

Follow this link:

With $52 Million Series A, Appia Bio Anticipates a Bright Future in Cell Therapy - BioSpace

Read more
The Univer-cell Alchemist: Dr Subhadra Dravidas breakthrough research on novel stem cell treatment for Covid patients – The New Indian Express

Bio-entrepreneur Dr Subhadra Dravida is inspired by Paulo Coelho. Her favourite line is from The Alchemist When you seek something, all the Universe conspires in helping you to achieve it. Says the scientist and owner of healthcare startup Transcell Oncologics, Since the news of the virus erupted in March 2020, I had been thinking on these lines. And in three months it happened. If everything goes well, our solution will actually get implemented in a month or two in India. The Universe did step in and Dravida is the new medical star whose breakthrough research on a novel stem cell treatment holds promise for Covid patients.

In India, a young girl doesnt need a specific trigger to turn to research, seeking a solution to end mankinds trialsit is all-pervasive. Since her teens, this desire has driven Dravidas research. Ive always strongly felt that Im born to shield humans from suffering, she says, rather dramatically. An entrepreneurial technocrat who has worked in the US, Canada and India in stem cell research, biobanking and product development, Dravidas Hyderabad-based biotech startup was incubated at ASPIRE-Technology Business Incubator, University of Hyderabad. A week ago, the university announced that Dravidas research on human umbilical cord (UC) tissue has yielded a stem cell-based solution to successfully treat coronavirus patients.

Researcher to entrepreneur, what prompted the transition? Dravida had to wait for almost eight months for her hypothesis to be practical. An entrepreneur at the helm of decision making would have cleared such bottlenecks. Over time, Dravida acquired many patents to her credit which she desired to translate into Apps. She moved back to Hyderabad and established her own startup in 2011. This Nizam College, Hyderabad, alumna, who was listed in Forbes magazines 2019 W-Power Trailblazers list, says that the HEMATO UC-MSCs she evolved do not cause adverse effects, are easy to administer and are proven to be safe for human application. It will not damage organs.

How did a stem cell researcher find a treatment for Covid-19? During some academic discussions with doctors in Hyderabad this year, I was asked for an alternative after anti-viral medication and steroids options were exhausted. I realised that I can work on existing solutions with coronavirus-specific data and find a workable solution, says Dravida, whose experience working at the Centre for Cellular and Molecular Biology and the LV Prasad Eye Institute, Hyderabad, shaped the research. She is certain that the HEMATO UC-MSCs therapy is the new way to cure Covid-19 patients in real time, not just by treating their symptoms alone.

If HEMATO UC-MSCs are administered as the first line of treatment followed by steps to alleviate the symptoms in a traditional manner, coronavirus deaths can be avoided, she believes. HEMATO UC-MSCs can be delivered across India within 48 hours. They have been specially treated for storage under 2-8 degrees centigrade refrigerated conditions, but have to be used within 72 hours.

Dravidas team comprised, apart from herself, two junior colleagues, a fellow scientist and a marketing evangelist. She recalls conducting innumerable meetings with social distancing and Zoom calls to create a workable model. A colleagues mom barely in her 50s was admitted to hospital for emergency Covid treatment. I heard horror stories about the hospital rationing her oxygen supply. I prayed fervently that our solution would see the light of the day sooner to prevent more loss of life, she says. When Dravida is not poring over scientific journals, she loves to visit monasteries and gaze up at the night sky. Perhaps, the Universe has its ear cocked for this alchemist of life.

Understanding Mesenchymal Stem CellsStem cells provide new cells for the body and replace those that are damaged or lost. They can divide repeatedly to produce new cells. As they divide, they can also change into the other types of cells that make up the body. Stem cells originate from two main sources: adult body tissues and embryos. Scientists are working on ways to develop stem cells from other cells, using genetic reprogramming techniques. Mesenchymal stem cells (MSCs) are multipotent stem cells found in the bone marrow that are important for making and repairing skeletal tissues, such as cartilage, bone and the fat found in the bone marrow.

Continued here:

The Univer-cell Alchemist: Dr Subhadra Dravidas breakthrough research on novel stem cell treatment for Covid patients - The New Indian Express

Read more
Stem Cell Therapy Market 2021-2026: Industry Analysis, Geographical Segmentation, Drivers, Challenges, and Trend & Forecasts KSU | The Sentinel…

Intel Market Report presents a comprehensive report on the Stem Cell Therapy Market comprising all the key factors impacting the industry and the overall growth. They include the industry drivers, opportunities, challenges, prevailing trends, and restraints that help the business owners, marketing personnel, and stakeholders, and customers to plan effective strategies and achieve their short-term goals smoothly. The report involves extensive study of the historical data with detailed statistics to help the readers determine future scope of the Stem Cell Therapy market with respect to key opportunities. The updated report crucially inspects all the aspects in terms of production and consumption. This assists the readers and manufacturers to focus on production with complete information on consumption patterns of consumers, without excess production and reducing wastage and saving resources and raw materials.

Download FREE sample of the Stem Cell Therapy market here: : https://www.intelmarketreports.com/sample/4131

Comprehensive research report on the Stem Cell Therapy market delivers deep insights on the key categories including product types, applications, end users, and geography. Researchers have studied and delivered all the categories deeply to offer key insights to buyers regarding major highlights that help them to decide profitable strategies for the forecast period. Through well-researched report on Stem Cell Therapy market, business owners, manufacturers, distributors, suppliers, and customers can effectively plan various activities associated with production, earning profits, consumption, and gaining customers and establish their strong presence among competitors.

Additional Information: Experts have also presented the Stem Cell Therapy market report with impactful details for readers through graphical representation like pie chart, bar chart, tables, and statistics. Moreover, the report also delivers key impacting factors on the industry due to the prevailing COVID-19 situation. Researchers have deeply studied and analyzed the Stem Cell Therapy market from all aspects to offer crucial information to buyers regarding the divisions or domains affected by the presence of Coronavirus like logistics, production, slow or declined delivery of raw materials, reduced or increased consumption, variations in prices, and more. Besides, the report also precisely suggests the readers, businesses, and producers regarding tactics that could help them gain higher profits in the near future.

Geographically, the Stem Cell Therapy market is segmented as North America, Latin America, Europe, Asia Pacific, and Middle East and Africa. Researchers have delivered key insights on each of these regions including demographic information like age, gender, income, family, and more. This offer clear picture of the regional market to the business owners and assist them in planning crucial strategies.

Regional investigation includes: North America (U.S. and Canada) Latin America (Mexico, Brazil, Chile, and others) Europe (Germany, U.K., Spain, France, Italy, Russia, Poland, Netherlands, and Belgium) Asia Pacific (China, Japan, India, New Zealand, and Australia) Middle East and Africa (North Africa, Southern Africa)

Get Discount now: https://www.intelmarketreports.com/discount/4131

Table of Contents of Stem Cell Therapy Market: 1 Market Overview1.1 Stem Cell Therapy Introduction1.2 Market Study by Type1.2.1 Type 11.2.2 Type 21.3 Market Study by Applications1.3.1 Application 11.3.2 Application 21.4 Market Study by End User1.4.1 End User 11.4.2 End User 21.5 Market Study by Regions1.5.1 North America (United States, Mexico, and Canada)1.5.2 South America (Brazil, Argentina, and Columbia)1.5.3 Europe (Germany, UK, France, Italy, and Russia)1.5.4 Asia-Pacific (China, Korea, Japan, Southeast Asia, and India)1.5.5 Middle East and Africa1.6 Market Dynamics1.6.1 Market Risk1.6.2 Market Opportunities1.6.3 Market Driving Force2 Vendors Profiles2.1 Vendors2.1.1 Overview2.1.2 Stem Cell Therapy Type and Applications2.1.2.1 Product A2.1.2.2 Product B2.1.3 Vendor Stem Cell Therapy Sales, Price, Revenue, Gross Margin and Market Share (2021-2026)3 Global Stem Cell Therapy Sales, Revenue, Market Share and Competition by Vendor (2021-2026)3.1 Global Stem Cell Therapy Sales and Market Share by Vendor (2021-2026)3.2 Global Stem Cell Therapy Revenue and Market Share by Vendor (2021-2026)3.3 Market Concentration Rate3.3.1 Top 3 Stem Cell Therapy Vendor Industry Share in 20183.3.2 Top 6 Stem Cell Therapy Vendor Industry Share in 20183.4 Market Competition Trend4 Sales Channel, Distributors, Traders and Dealers4.1 Sales Channel4.1.1 Direct Marketing4.1.2 Indirect Marketing4.1.3 Marketing Channel and Future Trend4.2 Distributors, Dealers, and Traders5 Study Findings and Conclusion6 Appendix15.1 Data Source15.2 Methodology

Buy Exclusive Report @ https://www.intelmarketreports.com/checkout/4131

The detailed report on Stem Cell Therapy market covers extensive research through surveys, observations, interviews, and analysts as well as secondary research comprising industry body records, trustworthy paid sources, trade journals, and more. The study also presents quantitative and qualitative analysis by examining data collected by market analysts and participants. Study on Stem Cell Therapy market also contains separate investigation on the trends, opportunities in the micro and macro indicators, mandates, and regulations are covered. Stem Cell Therapy market research report further states details and comparison of previous records and current trends to offer better decision making scope to the business owners, strategy planners for better profits in the forecast period.

Key findings from this research report: The report offers a quantitative and qualitative analysis of the current Stem Cell Therapy Market trends, forecasts, and market size from 2021 to 2025 to identify new opportunities. Porters Five Forces analysis presents the strength of suppliers and buyers to enable stakeholders to plan effective strategic business decisions and identify the level of competition in the market. Top impactful factors & major investment pockets are highlighted in the study. The key countries in each region are analyzed including highlights on their revenue contribution.

The market player positioning segment offers an understanding of the present position of the market players active in the Stem Cell Therapy Market.

The research delivers detailed segmentation of the global Stem Cell Therapy Market. Major segments analyzed in the research comprise battery type, application, and region. Extensive analysis of sales, growth rate, revenue, and market share of each FF and GG for the historic period as well as the forecast period is delivered with the help of graphical presentation like tables and charts.

About us: Intel Market Reports is one stop solution for market research reports in multifarious businesses. We serve 300+ clients with 40,000+ different industry reports. IMR also offers customized market research reports with information ranging from the previous years to existing trends and opportunities for the report buyers for their benefit from the best publishers from aroung the globe.

Contact Us-+1 315 675 5103 (US)info@intelmarketreports.comsales@intelmarketreports.com

Continue reading here:

Stem Cell Therapy Market 2021-2026: Industry Analysis, Geographical Segmentation, Drivers, Challenges, and Trend & Forecasts KSU | The Sentinel...

Read more
Hope, hype and exploitation the wild history of stem cell science – ABC News

Stem cells and regenerative medicine have been heralded since the mid-20th Century as the best hope for curing countless physical ailments.

Decades later, there have been perhaps as many scandals in this field of medicine, as there have been genuine advances in research and application; and the full potential of stem cells is yet to be realised.

Physician-scientist Professor John Rasko de-mystifies the science by sharing stories of some of the field's most influential and infamous figures.

He also explains why there's still plenty of reason to be hopeful.

Flesh Made New: The Unnatural History and Broken Promise of Stem Cells by John Rasko and Carl Power is published by Harper Collins

Professor John Rasko is the Head of Department of Cell and Molecular Therapies at Royal Prince Alfred Hospital, and the Gene and Stem Cell Therapy Program at the centenary Institute, University of Sydney

John is a featured guest of Griffith University's Integrity 20

Listen to John's 2018 Boyer Lectures

Continue reading here:

Hope, hype and exploitation the wild history of stem cell science - ABC News

Read more
Scientists create first-of-its-kind 3D organoid model of the human pancreas – Newswise

Newswise Boston This year, more than 60,000 adults in the United States will be diagnosed with pancreatic cancer and, statistically, as few as 10 percent will survive five years after diagnosis, according to the American Cancer Society. Because pancreatic cancer is hidden deep within the body and often symptomless, its frequently diagnosed after the disease has progressed too far for surgical intervention and/or has spread throughout the body. Research indicates that earlier detection of pancreatic tumors could quadruple survival rates; however, no validated and reliable tests for early detection of pancreatic cancer currently exist.

Now, researchers at the Cancer Research Institute at Beth Israel Deaconess Medical Center (BIDMC) have successfully created the first three-dimensional (3D) organoid models of the pancreas from human stem cells. Unlike previous platforms for the study of pancreatic cancer, this first-of-its-kind organoid model includes both the acinar and ductal structures that play a critical role in the majority of pancreatic cancers. The new research platform which is not expected to guide patient care at this time will shed new light on the origins and development of pancreatic cancer, as well as reveal potential means for discovering markers of early diagnosis and monitoring the disease. The teams report appears in Cell: Stem Cell.

We thought, if we had a way to use human pancreatic cells to forward engineer cancer, we could begin to understand the earliest steps in the development of this disease, said corresponding author Senthil Muthuswamy, PhD, Director of Cell Biology at the Cancer Research Institute at BIDMC. This model could also serve as a platform to potentially discover biomarkers measurable changes linked to disease that we hope to use in the clinic to monitor cancer development.

The pancreas is a hormone-secreting organ consisting of ducts and acinar cell, structures. Researchers suspect that the most common kind of pancreatic cancer (pancreatic ductal adenocarcinoma, or PDAC) arises in the cells lining acinar and ductal structures. However, until now, scientists have not been able to successfully grow and maintain human acinar structures in the lab challenging their ability to test the hypothesis in a model.

To coerce the stem cells down the path to becoming ductal and acinar cells, Ling Huang, Instructor or Medicine at BIDMC in the Muthuswamy laboratory collaborated with Doug Meltons laboratory at Harvard University and methodically tested various combinations of cell growth media used for different lengths of time. The culmination of five-plus years of work, presented in the study represents the first time researchers successfully generated human acinar cells in culture and maintained them long enough to be able to use them in experiments.

Its like a cooking recipe a complex recipe, with no precedent, said Muthuswamy, who is also Associate Professor Medicine, Harvard Medical School. Only when you use all the right ingredients in the right proportions and do them in the correct sequence do you get the cells becoming the acinar cells.

Next, Huang and Ridhdhi Desai, a Research Fellow at BIDMC, used the two separate lineages of ductal and acinar organoids, engineered to include gene mutations known to be associated with pancreatic cancer. When the organoids were later implanted into mice, the different lineages behaved in distinct, predictable ways. For example, one mutation caused seven out of 10 of the mice transplanted with acinar-like organoids to develop cellular changes analogous to early pancreatic cancer in humans.

Understanding the mechanisms that regulate these events will provide important insights into the events regulating the initiation of pancreatic cancer, said Muthuswamy, who stressed that direct use of this acinar organoid technology for patients who have cancer today may be limited. The idea is to see if we can identify biomarkers to benefit future patients including by screening those at high risk for pancreatic cancer, so we can catch it before its too late.

Co-authors also included Dipikaa Akshinthala, Christine Maria Lim, Raul Gonzalez, Lakshmi B Muthuswamy of BIDMC; Daniel N. Conrad and Zev Gartner of University of California San Francisco; Nayara Carvalho Leite of Harvard University.

This work was supported by Institutional startup funds and UO1 (CA224193); F32 fellowship (F32GM115201); seed grant from Hirschberg Foundation for Pancreatic Cancer Research; and R01 from NIGMS (R01GM135462).

The authors declare no competing interests.

About Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. BIDMC is the official hospital of the Boston Red Sox. For more information, visitwww.bidmc.org.

Beth Israel Deaconess Medical Center is a part of Beth Israel Lahey Health, a health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,000 physicians and 35,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.


Read more here:

Scientists create first-of-its-kind 3D organoid model of the human pancreas - Newswise

Read more
Researchers map the first complete atlas of single cells that make up the human teeth – News-Medical.net

Researchers at the University Zurich have mapped the first complete atlas of single cells that make up the human teeth. Their research shows that the composition of human dental pulp and periodontium vary greatly. Their findings open up new avenues for cell-based dental therapeutic approaches.

During the last 30 years, medical and dental research has attracted a large number of scientists and practitioners working on aspects of high medical relevance that involve a combination of genetic and tissue regeneration approaches.

These developments in stem cell and tissue engineering have provided medical and dental researchers with new insights and given rise to new ideas as to how everyday clinical practice can be improved. Many research groups are dealing with questions like: How can we help injured tissues and organs heal? Can lost tissue be regenerated? How can we create solid protocols that apply across all stem cell therapies?

A team of researchers led by Thimios Mitsiadis, professor at the Institute of Oral Biology at the University of Zurich, and Dr. Andreas Moor, professor at the Department of Biosystems Science and Engineering at ETH Zurich, has now created the first-ever single cells atlas of the human teeth.

By using advanced single-cell sequencing technology, they were able to distinguish every single cell that is part of the dental pulp and the periodontium.

Our study provides an unprecedented understanding of the composition of these two tissues, which are subject to tooth-specific and bacterially-linked pathologies such as caries and periodontitis. Both the dental pulp and the periodontium contain stem cells that possess a great regenerative potential."

Pierfrancesco Pagella, Study First Co-Author and Senior Researcher, Mitsiadis' Team

The study identified great cellular heterogeneity in the dental pulp and the periodontium. Unexpectedly, the team found that the molecular signatures of the stem cell populations were very similar.

"We think their different behavior is possibly brought about by their distinctive microenvironment," says Pagella. The findings suggest that the microenvironmental specificity is the potential source of the major functional differences of the stem cells located in the various tooth compartments.

The study demonstrates the complexity of dental tissues and represents a major contribution to a better understanding of the cellular and molecular identity of human dental tissues.

"Single-cell approaches can help us understand the interactions of dental pulp and periodontal cells involved in immune responses upon bacterial insults. Therefore, single-cell analysis could be useful for diagnostic purposes to support the early detection of dental diseases," last author Thimios Mitsiadis explains. The findings thus open up new avenues for cell-based dental therapeutic approaches.

According to Mitsiadis, these advances in dental research can lead to more appropriate therapies, successful regeneration of damaged parts of the teeth, and even more precise diagnostic tools in case of dental pathologies. "These innovations are the consequence of the fusion between bioinformatics and modern dentistry," he concludes.


Journal reference:

Pagella, P., et al. (2021) A single-cell atlas of human teeth. iScience. doi.org/10.1016/j.isci.2021.102405.

Go here to read the rest:

Researchers map the first complete atlas of single cells that make up the human teeth - News-Medical.net

Read more